Last reviewed · How we verify

Rockwell Medical Technologies, Inc. — Portfolio Competitive Intelligence Brief

Rockwell Medical Technologies, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SFP SFP marketed Intravenous iron replacement agent Iron (Fe3+) for hemoglobin synthesis and erythropoiesis Hematology / Nephrology
Triferic AVNU Triferic AVNU marketed Iron replacement agent Iron (Fe3+) delivery system Nephrology / Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American Regent, Inc. · 2 shared drug classes
  2. Ain Shams University · 1 shared drug class
  3. Albina Nowak, MD · 1 shared drug class
  4. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
  5. Azad Pharma AG · 1 shared drug class
  6. CN NGANOU-GNINDJIO, MD, MSc · 1 shared drug class
  7. China-Japan Friendship Hospital · 1 shared drug class
  8. AMAG Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Rockwell Medical Technologies, Inc.:

Cite this brief

Drug Landscape (2026). Rockwell Medical Technologies, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rockwell-medical-technologies-inc. Accessed 2026-05-17.

Related